Optimizing Alt-Seafood Production with AQUA Cultured Foods

Today we’re thrilled to announce our new partnership with AQUA Cultured Foods!

AQUA has chosen Ginkgo to help optimize its innovative fermentation technology to elevate the quality of its fish-free seafood products that authentically replicate the look, feel, and taste of fresh-caught seafood. Leveraging Ginkgo’s microbial characterization and analytics, along with AQUA’s proprietary strains and processes, the partners aim to transform the future of alt-seafood production.

AQUA is a leader in the alternative seafood industry, delivering products with the texture, taste, and appearance of fresh-caught seafood filets, without using any fish or animal inputs.

  • Their debut offerings, tuna, and scallops, maintain freshness and tenderness for six weeks.
  • Powered by a patent-pending fermentation process, which can be scaled on a global level, AQUA’s fish-free seafood is made from microbes and fibers combined with plant-derived flavors that replicate the buttery texture and umami notes found in fresh-caught seafood.
  • Unlike traditional seafood, AQUA’s products contain no contaminants, antibiotics, allergens, cholesterol or saturated fats, and can be consumed and enjoyed by those with diverse dietary needs, including pregnant people and those with shellfish allergies.

The AQUA team uses a consortium of microbes that work synergistically to make its appetizing and affordable products.

Ginkgo will leverage its high throughput next-generation sequencing and advanced analytics services to help optimize and tune AQUA’s strains to aid in the scale-up of their novel manufacturing process. With Ginkgo, AQUA hopes to amplify its R&D capabilities and further optimize its consortium to establish consistent, high-quality products.

Through this, AQUA envisions a future where its proprietary microbe consortium can be used to produce not just whole-cut and ground alt-seafood products, but also introduce unique flavors and textures to the broader food industry.

This inaugural partnership paves the way for future projects leveraging Ginkgo’s strain engineering capabilities as well.

AQUA’s fermentation process provides an alternative to fishing and fish farming.

Research shows that there are serious health risks associated with eating both wild-caught seafood from the ocean and farmed fish. The U.S. Environmental Protection Agency states that contaminated fish are a persistent source of toxic polychlorinated biphenyls (PCBs) and mercury in the human diet. Eating farmed fish comes with the added risk of consuming antibiotics and pesticides.

Both the fishing and fish farming industries cause detrimental environmental damage. Wild fisheries have been depleted worldwide, causing scientists to fear their impending collapse. Industrial fishing practices, such as bottom trawling and long-lining, affect endangered animals such as sea turtles, dolphins, and whales. Untreated waste from farmed fish — including excess feed, decomposing fish, excrement, and chemical residue — can pollute waterways and create toxic algal blooms that kill wild aquatic life. AQUA is confident that its products deliver the experience of eating seafood without the health or environmental risks associated with traditional seafood.

“Today marks a significant step towards revolutionizing alternative seafood production. AQUA’s commitment to sustainable seafood aligns with Ginkgo’s dedication to innovation. Our partnership aims to accelerate our technology, bringing our delicious products to market faster. With Ginkgo’s expertise in working with microbes, we are confident in optimizing and applying our technology to create the most delicious seafood products possible. Beyond sequencing, we envision engineering our proprietary consortium for next-gen products, pushing alt-seafood boundaries with unique textures and building the nutrition beyond a good source of fiber. We look forward to how our sustainable approach can revolutionize the fishing industry and contribute to the regeneration of our oceans.”

Stefan Baier, PhD, Chief Science Officer of AQUA Cultured Foods

We couldn’t be happier to partner with AQUA and get to work with their cutting-edge technology.

This collaboration aligns beautifully with our commitment to work on projects that embody innovation and sustainability. AQUA’s groundbreaking fermentation technology is reshaping the future of alt-seafood, and we at Ginkgo are thrilled to contribute to this transformative journey. Together, we’re paving the way for a more sustainable and responsible approach to meeting the world’s growing food demands.

AQUA will also be at Ginkgo’s annual Ferment conference this year on April 11th.

Baier will be presenting at the conference, and AQUA products will be available for conference attendees to taste.

Discovering and Manufacturing Next-Generation Vaccine Adjuvants Using Generative Molecular Design


We’re thrilled to have been awarded a 5-year contract alongside SaponiQx, Inc., totaling up to $31 million including program options, to discover and develop next-generation vaccine adjuvants.

This award comes to us from the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, “Adjuvant Activity to Vaccines Prototype.”

We’ve been partners with SaponiQx in adjuvant discovery and development since 2021, and we’re honored to work with them on this project. Together, we will use a combination of high-throughput empirical and artificial intelligence/machine learning approaches, including Generative Molecular Design (GMD), to develop superior novel saponin-based adjuvants.

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination. Currently, only a handful of adjuvants are available for human use in licensed vaccines. SaponiQx’s STIMULON™ QS-21 is a key adjuvant component in market-leading vaccines for shingles, malaria, and respiratory syncytial virus. Novel adjuvants with enhanced properties, including tailored humoral and cellular immune responses, could pave the way for a new wave of innovative vaccines against existing and emerging pathogens.

The COVID-19 pandemic revealed the critical need for safe, effective, and accessible vaccines against emerging biothreat agents.

Imagine a future where vaccines are not only more affordable but also provide consistent protection in fewer doses, without causing discomfort or requiring refrigeration. We’re very excited by this opportunity to strengthen and expand the SaponiQx–Ginkgo partnership and to work with DTRA to make that future a reality.

Building on our achievements with STIMULON QS-21, SaponiQx is excited to realize our company’s founding vision of harnessing the potential of Generative Molecular Design to dramatically increase access to lifesaving vaccines around the world.

Rebecca Kurnat, Head of Operations at SaponiQx

We aim to demonstrate in the laboratory and in animal studies the ability of these novel adjuvants to protect against challenges from biothreat agents, such as the plague, and to provide lower cost, sustainable and scalable manufacturing processes by leveraging Ginkgo’s leading platform for cell programming. Together, we intend to design candidate adjuvants using SaponiQx’s leading platform for adjuvant generation, and to identify additional candidates by screening natural extracts for previously uncharacterized saponins and creating non-natural saponins with enzyme-based techniques. Harnessing a first-of-its-kind “data lake” for adjuvants, we plan to use iterative GMD to propose and optimize adjuvant structures against eight functional parameters. Adjuvant candidates will be put through in-depth testing, first in the laboratory for immune and toxicity responses, and then in studies of their effectiveness in protecting vaccinated animals from pathogens; QS-21 and the related QS-7 will serve as benchmarks.

By leveraging our leading platform for cell programming, we also intend to develop more affordable, sustainable, and scalable adjuvant manufacturing processes.

Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers’ yeast, Saccharomyces cerevisiae. Our platform powers iterative Design–Build–Test–Learn-driven cell engineering to enable the rapid prototyping, optimization, and development of proteins, enzymes, metabolic pathways, and whole organisms under commercial-scale manufacturing conditions. Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

Successful First Milestone to Produce Vibrant Natural Food Colors with Phytolon

We’ve successfully completed the first development milestone of our multi-product collaboration with Phytolon to produce natural food colors!

This achievement has resulted in the distribution of an equity milestone to Ginkgo.

Our partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering. The completion of our first milestone has unlocked the commercial potential of Phytolon’s yellow-to-purple palette and further established this broad and cost-efficient offering to its clients.

By leveraging Ginkgo Natural Product Services, Phytolon has significantly improved the efficiency of its yeast strains to generate these vibrant, sustainable colors and offer cost-efficient replacements to artificial dyes.

Phytolon’s naturally produced betalain pigments can be used throughout the food industry as safe, sustainable, and viable alternatives to synthetic dyes, which are facing increased scrutiny and bans. As governments continue to intensify regulations on synthetic dyes, consumers will increasingly seek out more sustainable and nature-derived products. By partnering with Ginkgo, Phytolon is in a strong position to scale their robust array of food colorants for the global market.

Phytolon soon expects to bring the full color palette enabled by these two new strains to market.

We will continue to work together under our existing agreement toward achieving additional milestones that further increase production efficiency.

“We are so excited to reach this key milestone with our partner, Ginkgo Bioworks. This achievement puts our colors at the forefront to efficiently replace artificial dyes in our food and create a healthy and sustainable world. Our clients are now able to explore high-performing natural colors in their brands, covering the full range from purple to pink, red, orange, and yellow shades.”

Tal Zeltzer, co-founder and CTO of Phytolon

We’re proud to be a driving force behind the realization of this milestone and the R&D breakthroughs it represents. Ginkgo Natural Product Services have enabled Phytolon’s products to be competitive worldwide and create a broader palette of options for the industry. We’re happy to be able to provide innovators like Phytolon with our services and give access to our codebase to accelerate their product development. As we celebrate this success, we look forward to sustaining this momentum to further enhance the performance of Phytolon’s products.

Learn more about Ginkgo Natural Product Services at https://www.ginkgobioworks.com/offerings/natural-products-services/.

And read Ginkgo’s whitepaper on the Bioproduction of Aromatic Molecules at https://www.ginkgobioworks.com/offerings/whitepaper-bioproduction-of-aromatic-molecules/.

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

Today we’re thrilled to provide updates on our business at the J.P. Morgan Healthcare Conference in San Francisco, live and on webcast at 9:45am PT/12:45pm ET.

In short, we:

  • Expect to meet our 2023 new program and revenue guidance ranges
  • Ended 2023 with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as we see operational efficiencies in our business
  • See strong growth among blue chip pharma and biotech (“biopharma”) customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim
  • Will highlight more updates today at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) here.

I’m very pleased with the robust revenue and program growth we have seen in 2023, particularly in the biopharma sector – growing the portion of our cell engineering revenue that is attributable to biopharma customers by more than 50% over the past year.

Our strong balance sheet, with nearly $950 million of cash and cash equivalents, positions us well to take advantage of strategic opportunities while the market faces continued pressure. This, combined with the meaningful improvements we have seen in operational efficiency, gives us a long runway as we plan to increase new programs while reducing operating expenses. I’m proud of our team’s accomplishments in 2023 and am excited to drive continued strong growth in our biopharma vertical in 2024.

Preliminary 2023 Key Performance Highlights

  • Ginkgo continues to expect Total revenue of $250 – $260 million in 2023
    • Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023
    • Preliminary unaudited Biosecurity revenue is expected to be in line with the previously disclosed guidance of up to $110 million in 2023
  • New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023
  • Ginkgo signed or advanced several major new biopharma programs in 2023, including with Pfizer, Merck, Novo Nordisk, and Boehringer Ingelheim in which Ginkgo is eligible to receive, in aggregate, over $1.2 billion in upfront research payments, research fees and development and commercial milestones. Ginkgo also successfully completed the pilot phase of a program with Novo Nordisk, as well as completed a gene therapy collaboration with Biogen.
  • In connection with its strategic partnership with Google Cloud, Ginkgo is training a series of foundation and application-specific models incorporating Ginkgo’s proprietary metagenomics and assay-labeled training data as well as data from public repositories. Ginkgo’s ability to bring together automated data generation at scale with AI models targeted towards customer program areas is expected to be the foundation for additional pharmaceutical partnerships in 2024.
  • Ginkgo ended 2023 with nearly $950 million of cash and cash equivalents, putting Ginkgo in a strong financial position to pursue its strategic objectives while driving towards profitability

We plan to report fourth quarter and full year 2023 financial results in February 2024, at which time we intend to provide our outlook for full year 2024.

To learn more about Ginkgo’s biopharmaceutical services offerings, visit https://www.ginkgobioworks.com/offerings/biopharmaceutical/.

What will you grow with Ginkgo?

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Today we’re thrilled to announce the formation of our new Biopharma Advisory Board!

This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo’s core platform service offerings across target discovery, drug discovery, optimization, and manufacturing. The group, which will conduct regular meetings at Ginkgo and with its partners, includes (in alphabetical order) —

  • Norbert Bischofberger, PhD, is the President and Chief Executive Officer of Kronos Bio, a clinical-stage biopharmaceutical company developing medicines that target the deregulated transcription that is the hallmark of cancer and other serious diseases. Prior to Kronos, Dr. Bischofberger spent 28 years at Gilead, where he presided over the development and approval of more than 25 medicines for a range of serious conditions, including the transformation in the treatment of diseases such as HIV and viral hepatitis. Notably, he is one of the inventors of Tamiflu, an oral medication on the market for both the prevention and treatment of influenza A and B. Norbert was part of the core management team that grew Gilead from less than 50 employees with no revenues to 10,000 employees with $25B in revenue.
  • Jeff Legos, PhD, MBA, is currently an Executive Vice President and Global Head of Oncology and Hematology at Novartis, where he leads development, registration, approval, and life cycle management for a clinical pipeline of 35+ assets across a broad range of cancers and blood disorders. Dr. Legos has a proven track record of successfully leading large multinational teams across all functions and stages of R&D in both his current and previous role as Vice President and Global Medicine Development Leader at GlaxoSmithKline, which has resulted in more than 30 global regulatory drug and companion diagnostic approvals.
  • John Maraganore, PhD, served as the founding Chief Executive Officer and a Director of Alnylam from 2002 to 2021. Under his leadership, Alnylam helped lead the interventional RNA revolution by launching the first RNAi therapeutic medicine, ONPATTRO®, in 2018, followed by four more RNAi therapeutics through mid-2022. Dr. Maraganore was the chair of the Biotechnology Innovation Organization (BIO) from 2017 to 2019 and is an active mentor to leaders across the biotechnology industry. John is the principal of JMM Innovation, and also serves as a Venture Partner for Arch Ventures and Atlas Ventures, an executive partner for RTW Investments, a senior advisor for Blackstone Life Sciences, and as an advisor for M28.
  • Paolo Martini, PhD, is the Chief Scientific Officer of International Therapeutic Research Centers and the Founder of Rare Diseases at Moderna, where he previously worked on messenger RNA therapy for rare and orphan diseases. He has more than 20 years of experience in drug discovery working on molecular mechanisms underlying monogenic and multigenic metabolic and fibrotic disorders as well as hematologic malignancies.
  • Mark McCamish, MD, PhD, is the President & Chief Executive Officer of IconOVir Bio, a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. He was previously the President & Chief Executive Officer of Forty Seven, which he led from a valuation of $169M to an acquisition by Gilead for $4.9B. Previously he has had extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz and is a renowned expert in biologic and biosimilars development and manufacturing.
  • Christi Shaw is an Independent Director on the Boards of Beam Therapeutics, ReAlta Life Sciences, and Avantor. She previously served as Chief Executive Officer of Kite Pharma and as Senior Vice President at Eli Lilly & Company, where she was President of Lilly Bio-Medicines. Ms. Shaw has also held prominent leadership roles at Johnson & Johnson and Novartis where she served as US Country Head and President. Christi co-founded the More Moments More Memories Foundation which provides financial assistance to help cancer patients access potentially life saving clinical trials.

Together, this council represents a wide breadth of technical experience and deep business expertise that will contribute to the development of Ginkgo’s service offerings in Gene Therapy, Cell Therapy, RNA, Biologics, Process R&D and more.

Over the past year, we announced new R&D services collaborations with Boehringer Ingelheim, DARPA, Esperovax, Merck, Pfizer, Prokarium, Sensible, Synplogen, WARF, as well as advancements in its work with Novo Nordisk, Persephone Biosciences, and Synlogic. Ginkgo acquires and integrates new technologies to expand its horizontal platform, with past acquisitions serving to develop our capabilities in AAV and circular RNA.

The discovery and development of new medicines is critically important and incredibly challenging. Advanced technologies in high throughput automation, synthetic biology, and more recently AI, have opened up possibilities for the development of novel modalities and exploration of more design space for the discovery and optimization of new targets and candidate therapies.

It’s an incredibly exciting time for the industry as these technologies come together at scale, and we’re thrilled to have this group of luminaries as part of our inaugural cohort of advisors.

“I’m excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family,” said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks. “These leaders have shaped the modern vaccines and therapeutics landscapes by spearheading the discovery, testing, manufacturing, and deployment of entirely new modalities, and reinventing how researchers and drugmakers work with more familiar areas of medicine. I can’t wait to see how their mentorship, insights, and provocations help our growing team reach new heights.”

“We live in a global, interconnected society, and therefore, we are all susceptible to the spread of novel infectious diseases. Now more than ever, the speed of drug discovery and development is important,” said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member. “Ginkgo’s experience in accelerating biological R&D across modalities and their extensive work in biosecurity and epidemiology positions the company to make a meaningful impact. I look forward to supporting the growth of their team and offerings.”

“Ginkgo represents a huge opportunity for businesses who want to take new pharmaceuticals to market. By outsourcing risky R&D to a partner with unprecedented scale, companies can optimize their approach to new modalities and targets wherever they are in the pipeline,” said John Maraganore, Ginkgo Biopharma Advisory Board member. “Our industry is at a pivotal moment. More and more of biopharma can leverage scale and AI to turn scientific uncertainty into predictable engineering, so I’m thrilled to be able to contribute to the energy and movement I saw firsthand when I spoke onstage with Jen at Ferment.”

To learn more about Ginkgo’s biopharmaceutical services offerings, visit https://www.ginkgobioworks.com/offerings/biopharmaceutical/.

What will you grow with Ginkgo?

Completed Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform

Today we’re thrilled to announce the successful completion of our gene therapy collaboration previously announced with Biogen in May 2021!

Together, we aimed to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved our goals of enhancing the AAV production titers of Biogen’s gene therapy manufacturing processes.

We’re proud to work with industry-defining partners like Biogen to help global leaders in the biopharmaceutical industry redefine what’s possible in therapeutics discovery and manufacturing.

Significant improvements like these are the result of a platform-based approach to biological R&D. They are possible because our program leads work closely with our collaboration partners to take full advantage of the broad scale and deep sophistication of our highly-automated foundry and growing codebase.

Learn more about Ginkgo’s Gene Therapy Services here.

What will you grow with Ginkgo?

Year in Review: New Partnerships and Offerings in Agriculture in 2023

For Ginkgo, 2023 has been a banner year for serving companies leading innovation in agriculture. We’re grateful to be working with partners who are developing safe, efficacious, and consistent products for growers around the globe. Here’s our year in review.

Grateful to work with innovative partners

On the heels of expanding our ag biologicals R&D footprint and team, we entered a partnership with Syngenta, applying our encapsulation and screening technology (EncapS) to help them identify improved leads for novel plant traits. Learn more about our EncapS technology in this 5-minute video.

In addition to supporting novel traits, we also signed partnerships aimed at improving some of our partners’ existing products. These R&D programs aim to drive important commercial outcomes for our partners: strengthening their position in the biologicals market with higher-performing products or accessing greater market share by reducing unit costs of production. Read more about these collaborations:

  • AgBiome leverages our Rapid Strain Optimization services to improve product performance
  • Exacta Biosciences taps our fermentation optimization and formulation capabilities to drive down COGS of their biostimulant product, FitoRoot®
  • OneOne Biosciences will work with Ginkgo for in vitro and in planta assays to test OneOne’s Livepods™ product delivery concept. In a second phase, Ginkgo’s Rapid Strain Optimization services will aim to provide optimized strains for nitrogen fixation.

We’re thrilled to be partnering with Agrivalle to help strengthen their position in Brazil’s fast-growing ag biologicals market. Agrivalle has tapped us to be their innovation partner; we’re excited to bring our full spectrum of R&D capabilities to deliver higher performing biologicals and develop novel products that complement their existing portfolio.

And we couldn’t be more excited about our continuing partnership with Bayer, of course.

New service offerings for biologicals and traits

This year, we launched a suite of services for ag biologicals and plant traits innovators.

Our Product Headstarts aim to de-risk the early discovery part of new product development. Each Product Headstart comprises a set of strains that have undergone in silico, in vitro, and in some cases, in planta characterization focused on a specific product application. Even for partners that turn to in-licensing for portfolio growth, Product Headstarts offer the advantage of choice – partners work with Ginkgo to steer product specifications including application method and formulation. As innovation partners we work in tandem to set the standard for efficacy and consistency.

We launched our Rapid Strain Optimization services for ag biologicals this year, and both Agrivalle and AgBiome are utilizing these services to provide growers with better performing biologicals – up to 5x improved performance – using methods that are favored by regulators worldwide. Learn more about our proprietary technology underpinning this service offering in this recording of our Rapid Strain Optimization virtual event.

Novelty is key when it comes to developing plant traits. Ginkgo’s proprietary metagenomic database, our machine-learning guided protein design and optimization capabilities and our ultra-high throughput screening technologies underpin our Plant Trait services.

Contact us to learn more about these services.

Looking forward to next year

Next year, we’ll be launching new service offerings for biochemical production through fermentation. Naturally-secreted metabolites have tremendous potential as crop protection and nutrient use inputs. Many of these molecules can be produced by fermentation-friendly microbes. What’s more, this production method often enjoys wider regulatory acceptance as compared to whole microbial biologicals.

Ginkgo’s platform offers a range of unique benefits to help partners scale up biochemical production. First, we’ve optimized chassis strains with high flux across a range of small molecule classes: aromatics, terpenes, organic acids, amino acids – starting points for biochemistry that can impact crop protection and nutrition. Second, our pathway optimization and metabolic engineering capabilities lean on heavily automated workflows and troves of proprietary data relating gene sequences to function and structure.

If you’re curious about these services now, don’t hesitate to contact us using the form below!

We’re also excited to meet ag biologicals leaders and plant traits developers at conferences next year. Let us know if you’ll be attending any of the World Agritech conferences, ABIM or other great meetings in 2024!

What will you grow in 2024?

Advancing OneOne Biosciences’ Platform and Nitrogen Fixation Microbial Product

Today we’re thrilled to announce our partnership with OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers!

This collaboration will leverage our robust ag biologicals infrastructure, biotechnological expertise, and Strain Optimization Services to accelerate OneOne’s research and product development in agricultural microbial solutions.

OneOne’s mission is to equip growers with bio-based agricultural inputs characterized by both exceptional effectiveness and longevity. Central to this mission is OneOne’s development of a novel, universal solution for production and delivery of ag microbials through the OneOne Multiplier™, a user-friendly “espresso machine-type” device that amplifies microbes at the point of use. Users can insert OneOne Livepods™ into the Multiplier to aseptically prepare microbials, which can then be applied directly to crops. Livepods are designed to come loaded with microbes that are tailored for specific-use cases — e.g. nitrogen fixation, phosphate solubilization, crop protection, drought resistance, carbon sequestration, and more. This fresh approach, combined with other species-independent innovative components, aims to be forward compatible with future data-based product personalization, parametrized by individual crop and soil characteristics.

OneOne’s initial focus is on developing a Livepod for nitrogen fixation, a roughly $100 billion market. OneOne will work with Ginkgo for in vitro and in planta assays to test OneOne’s concept. In a second phase, Ginkgo plans to use its Strain Optimization Services and ultra high throughput encapsulated screening to provide optimized strains for nitrogen fixation. The strains may then progress to field trials and regulatory preparations before commercialization.

“We are building a platform to provide growers with a complete range of microbial solutions beneficial to their crops, soils, and bottom lines. We expect our products to maximize long-term agronomic performance and farmer ROI. We are excited by this strategic partnership with Ginkgo, as we believe they are the only player capable of bringing all the expertise, infrastructure, and experience needed to ensure effective and efficient handling of key lines of our ag biologicals research and product development. We are confident that Ginkgo’s comprehensive services can generate valuable strain assets and reduce time-to-market. We look forward to contributing to the ongoing transition from chemicals towards bio-based solutions in the agricultural space, as is happening in other large industries. We expect that, at scale, this transition can and will drive significant net positives for economies and the environment in years to come.”

OneOne’s founder and CEO, Julien Sylvestre

Our partnership underscores the growing role of synbio in agriculture.

We’re thrilled to assist OneOne in demonstrating their concept and to apply our deep experience with nitrogen fixation as we seek to deliver successful strains for their Livepods. We firmly believe ag biologicals represent the future of sustainable, successful agriculture, and we are eager to support innovators like OneOne in entering the market with cutting-edge solutions.

We are also so excited to welcome OneOne’s founder and CEO, Julien Sylvestre, to the stage at our Ferment 2024 conference!

You can learn more about Ferment 2024 here!

To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services

What will you grow with Ginkgo?

Ginkgo Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria

We’re thrilled to receive a grant from the Bill & Melinda Gates Foundation!

Under this grant, we will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.

Protein therapeutics have transformed the standard of care for many diseases — the best known example being insulin for diabetes — and have helped to extend lives across the world, thanks to revolutionizing treatments of diseases such as anemia, cancers, and certain genetic disorders. Yet access to these therapeutics remains a challenge, especially in low- and middle-income countries (LMICs), because of complex manufacturing processes and degradation during storage and delivery of such therapeutics. Developing a new therapeutic delivery modality for patients could increase accessibility and lower cost of treatment.

We will focus on creating a prototype engineered cell line that can express antibodies for the treatment of HIV and/or malaria via an implantable device.

Globally, approximately 39 million people live with HIV, which attacks the body’s immune system and weakens its ability to fight infection. The World Health Organization (WHO) reports that nearly half the world’s population is at risk of malaria transmission, with 96% of malaria-caused deaths in 2020 taking place in the WHO Africa Region. The engineered cell line would be designed to act as a “cell factory” capable of delivering protein therapeutics to the patient for up to a year, or longer. This prototype cell line could potentially lead to protein therapeutic delivery systems that function as long-term and cost-effective treatments for these diseases.

Ginkgo, with support from the foundation, plans to use its expertise in mammalian cell engineering to engineer highly synthetic cell lines that have both high productivity and extended longevity.

We will use our expertise in genomics and systems biology to predict the genomic components underlying these complex cellular phenotypes. We will then utilize our expertise in genome engineering, including a fully automated clonal cell line generation workflow, to combine these features in a mammalian chassis. This engineered cell line will be combined with an implant device for continuous delivery of the therapeutic antibodies. If successful, the eventual product could create a novel delivery platform for antibody-based therapies in communities where access to such drugs is challenging.

Protein-based drugs were some of the earliest applications of cell programming for medicine half a century ago. We’re honored to be receiving support from the Gates Foundation to reimagine how these medicines are made and delivered so that we can open up access to these critical therapies. We look forward to leveraging our learnings from this project to ensure the success of future programs with our partners.

Learn more about Ginkgo’s biopharmaceutical services at https://www.ginkgobioworks.com/offerings/biopharmaceutical/.

What will you grow with Ginkgo?

Advancing Discovery and Development of Precision Gene Editors with Arbor Biotechnologies

We’re so excited to announce our new collaboration with Arbor Biotechnologies!

Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases. The company’s portfolio of novel gene editors has significant therapeutic potential due to, among other things, their unique protospacer adjacent motifs (PAMs), which may enable access to nearly all sites in the genome, their varied cut types, which can potentially correct a wider range of diseases, their smaller editing technology, which allows the use of additional delivery technologies, and their high specificity, which can enable improved safety profiles.

Ginkgo’s expertise in high throughput exploration of genetic design spaces complements Arbor’s in-house capabilities, and the collaboration is expected to accelerate Arbor’s precision editor optimization campaign through massively parallel library design, automated mammalian cell experimentation and iterative AI-guided protein engineering.

“Patients are at the center of everything we do at Arbor, and we are thrilled to partner with Ginkgo to hasten the advancement of our precision editing technologies into therapeutic applications that have the potential to address diseases with high unmet medical need. Ginkgo’s expertise aligns well with our goals, and their technology will synergize with our in-house capabilities, potentially fueling a faster, more efficient expansion of our toolbox of gene editing technologies.”

Devyn Smith, Ph.D., CEO of Arbor

As we can see from the recent landmark regulatory approval of the world’s first CRISPR-based treatment, the gene editing landscape is rapidly advancing, with continuous innovation and optimization of novel technologies that are revolutionizing the way we consider and address disease. This collaboration with Arbor is an exciting project for us, as it gives us an opportunity to leverage our platform-driven approach to contribute to the gene editing sector’s fast-moving evolution.

We look forward to expanding our capabilities in this field by working with such an innovative pioneer as Arbor to power technologies with the potential for transformative impact.

What will you grow with Ginkgo?